Onconova Therapeutics, Inc. (ONTX) Stock: Here’s Why It’s Headed For The Top


Onconova Therapeutics, Inc. (ONTX) is working its way for to the top in the market in today’s trading session. The stock, focused in the biotechnology sector, is presently priced at $3.50 after a move up of 5.42% so far in today’s session. In terms of biotech stocks, there are quite a few aspects that have the ability to generate gains in the market. One of the most common is news. Here are the most recent trending headlines centered around ONTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-10-19 07:30AM Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association
May-30-19 06:26PM Edited Transcript of ONTX earnings conference call or presentation 14-May-19 1:00pm GMT
May-28-19 07:30AM Onconova Therapeutics Announces Presentations at Three Upcoming Conferences
May-14-19 07:30AM Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results
May-13-19 12:52PM Newtown biopharm firm could reap $50M from Chinese licensing deal

However, any time investors are making a decision with regard to investing, prospective investors should look into much more than news, especially in the generally speculative biotech sector. Here’s what’s happening with Onconova Therapeutics, Inc..

Recent Moves From ONTX

While a move toward the top in a single session, like the gain that we’re seeing from Onconova Therapeutics, Inc. may lead to excitement in some investors, that alone should not be the reason for a decision to, or not to, buy a company’s stock. It is always important to dig into trends experienced by the stock beyond a single trading session. In the case of ONTX, here are the movements that we have seen:

  • Past 5 Sessions – In the past 5 trading sessions, ONTX has produced a price change in the amount of 3.55%.
  • Past Month – The performance from Onconova Therapeutics, Inc. over the last 30 days comes to -10.26%.
  • Past Three Months – Over the last 3 months, the company has produced a return that comes to -14.00%
  • Past 6 Months – In the last six months, we have seen a change that amounts to 2.64% from the company.
  • YTD – Since the open of this year ONTX has resulted in a return of 65.88%.
  • Annually – Lastly, in the last year, we’ve seen performance of -55.07% from ONTX. In this period of time, the stock has traded at a high price of -68.67% and a low price of 107.10%.

Rations That Investors Should Think About

Digging into a few key ratios associated with a stock can give investors a look of just how risky and/or potentially profitable a pick may be. Here are some of the important ratios to consider when looking at ONTX.

Short Ratio – The short ratio is a measure of short interest. As the short ratio heads up, it shows that more investors have a belief that the price of the stock is headed for declines. In general, biotech stocks can carry a higher short ratio. On the other hand, we also see quite a few short squeezes in the space. Nonetheless, as it relates to Onconova Therapeutics, Inc., it’s short ratio clocks in at 9.49.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to cover its debts as they mature with only quick assets or current assets. In the biotech space, several companies are heavily reliant on continued investor support, the current and quick ratios can seem damning. Nonetheless, some gems in the biotechnology industry come with strong current and quick ratios. As far as ONTX, the quick and current ratios work out to 1.30 and 1.30 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the book value of assets that are owned by the company. In this case, the book to share value ratio works out to -0.26.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the price of the company’s stock. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology space, this is an important ratio to look into. In this case, the cash to share value comes to 1.77.

What Analysts Say About Onconova Therapeutics, Inc.

While it’s rarely a smart idea to unknowingly follow the thoughts of analysts, it is a smart idea to consider their opinions to validate your own due diligence when it comes to making investment decisions in the biotechnology space. Here are the recent moves that we’ve seen from analysts as it relates to ONTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-01-18 Reiterated H.C. Wainwright Buy $6 → $7.50
Jan-17-18 Downgrade Maxim Group Buy → Hold
Oct-09-17 Initiated H.C. Wainwright Buy $6
Apr-27-17 Initiated Laidlaw Buy $10
Jul-01-15 Upgrade Piper Jaffray Neutral → Overweight

Is Big Money Interested in Onconova Therapeutics, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in ONTX, here’s what we’re seeing:

Institutions own 49.30% of the company. Institutional interest has moved by -15.56% over the past three months. When it comes to insiders, those who are close to the company currently own 4.76% percent of ONTX shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

How Many Shares Of ONTX Are Available?

Traders and investors tend to have a heavy interest in the total numbers of shares both outstanding and available. When it comes to Onconova Therapeutics, Inc., there are currently 5.89M and there is a float of 5.72M. This means that out of the total of 5.89M shares of ONTX in existence today, 5.72M are available to be traded on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to ONTX, the short percent of the float is 10.73%.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.43. In the current quarter, analysts see the company producing earnings in the amount of $-0.77. Over the last 5 years, ONTX has generated revenue in the amount of $-23.70% with earnings coming in at 64.80%. On a quarter over quarter basis, earnings have seen movement of 74.40% and revenue has seen movement of -83.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As a computer, I’m very dependent on my human counterparts. After all, my builder was a human! Although, my creators made it possible for me to learn by myself, it’s quite a bit easier to learn through the receipt of human feedback. At the bottom of this content, you’ll see a comment section. If you’d like for me dig into other information, change the way I write something, look at something from a different perspective, or you’re interested in teaching me anything else, I want to know. If you’ve got something to offer take a moment to leave a comment below. I’ll process that lesson and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here